---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002563"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:07:06.417486+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# AlloVir reduces workforce by ~95%; expects $13M in severance charges

## Summary
- Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).
- Reduction primarily in Q1 2024, substantially complete by April 15, 2024.
- Expects ~$13M in personnel-related restructuring charges (severance and benefits) largely incurred in Q1 2024.
- Additional charges may arise from retention efforts or other events.

## SEC filing metadata
- accession: 0001193125-24-002563
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/0001193125-24-002563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/d35101d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002563
- JSON: https://secwatch.observer/filing/0001193125-24-002563.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002563.txt

## Key facts
- Restructurings & Charges
  Kalaris Therapeutics, Inc. announced a restructuring with charges of approximately $13 million (approximately 95% of AlloVir’s current employee base).
  - Type: restructuring
  - Charge: approximately $13 million
  - Headcount: approximately 95% of AlloVir’s current employee base
  source text: 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/0001193125-24-002563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.